Novo Nordisk Navigates a Pivotal Year of Challenge and Innovation

As Novo Nordisk looks ahead to 2026, the pharmaceutical giant is preparing for a significantly more challenging business climate while simultaneously launching one of its most critical product initiatives in recent memory. This dual narrative of mounting pressure and strategic offense defines the company's current crossroads.

In a direct response to intensifying competition, Novo Nordisk is betting on a major product expansion. The company has introduced the first oral GLP‑1 pill for weight management in the United States—a tablet version of its blockbuster drug, Wegovy. This move is strategically designed to defend its strong position in the lucrative obesity market while accessing new patient demographics.

The tablet specifically targets individuals who have been hesitant about injectable treatments, thereby substantially widening the potential market. The launch is supported by an aggressive pricing strategy aimed squarely at the self-pay segment:

• The introductory price for the daily oral Wegovy version is set at $149 per month.
• Maintenance doses for cash payers range from $199 to $299 per month.
• These prices are notably below the listed price of approximately $1,000 for the injectable form, which is also typically discounted.

Company leadership now projects that oral weight-loss medications could account for a third or more of the total GLP‑1 market by 2030—an outlook more optimistic than previous assessments. If this trend materializes, the tablet is poised to become a central growth engine for Novo Nordisk's portfolio.

Mounting International Headwinds

During the recent J.P. Morgan Healthcare Conference, CEO Mike Doustdar indicated that the company's international operations are likely to face pressure in 2026. A primary driver is the impending loss of market exclusivity for several products in multiple countries. As patents expire, the entry of lower-cost competitors typically squeezes margins and erodes market share.

The competitive landscape is also broadening overall. The expanding global presence of rival Eli Lilly across various regions is viewed as a central challenge. Doustdar acknowledged that Novo Nordisk's historically dominant market share in many areas presents a clear target for competitors seeking to gain ground.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Furthermore, the obesity market itself is undergoing structural change. Online distribution and cross-border sales are growing in importance, forcing Novo Nordisk to adapt its commercial model to maintain momentum.

Share Performance: A Partial Recovery

The stock market reflects this complex mix of rising competition and new opportunities through volatile trading activity. Over the past seven days, Novo Nordisk shares advanced by 5.62%. Looking at a 30-day horizon, the gain stands at 19.78%. This rally has moved the equity meaningfully above its 52-week low of €39.05, with shares closing at €51.24 in the latest session.

Despite this recovery, the current share price remains approximately 41% below its 52-week peak of €87.10. This considerable gap underscores that the market continues to price in risks associated with the international business, indicating the prior period of weakness is not fully resolved.

2026 Outlook: A Delicate Balancing Act

The coming year appears set to be a delicate balancing act for Novo Nordisk. Expiring exclusivities and the heightened competitive threat from players like Eli Lilly are expected to pressure international growth and profitability. Concurrently, the launch of the oral Wegovy tablet opens new revenue streams, particularly in the self-pay market and among injection-averse patients.

Whether the growth in the obesity segment can more than offset the pressures from patent expirations will become evident in the revenue and margin trends of the upcoming quarters. With the oral GLP‑1 pill, Novo Nordisk has laid the groundwork to maintain a leadership role in an evolving market. The year 2026 will now serve as the proving ground for the durability of this strategy in the face of competition from Eli Lilly and other market participants.